Legislative Update: House Ways & Means, Senate Finance Committees Hold Hearings on the Care Coordination and Rising Health Care Costs

AMCP commends ACIP’s commitment to regularly reviewing the scientific evidence underlying national immunization recommendations. We recognize the importance of maintaining guidance that is both scientifically rigorous and operationally feasible across diverse care settings. In that spirit, we offer the following comments on the Committee’s ongoing consideration of vaccine safety and the hepatitis B vaccine birth-dose recommendation.

On Sunday, November 9, Senate Majority Leader Thune announced that he had reached an agreement with a group of 8 Democratic senators and the White House on a deal to end the longest shutdown in U.S. history. On Monday, November 10, the Senate approved the government funding bill by a vote of 60-40, which sends the legislative package back to the House of Representatives.

President Donald Trump announced a series of agreements with Eli Lilly and Company and Novo Nordisk to offer Most-Favored-Nation (MFN) prices on two GLP-1 therapies, semaglutide (brand names Ozempic and Wegovy) and tirzepatide (brand names Mounjaro and Zepbound). This marks the fourth and fifth publicly announced agreements between the Trump administration and pharmaceutical manufacturers, joining earlier announcements with Pfizer, AstraZeneca, and EMD Serono. The manufacturers also agreed to cap prices for insulin products and other commonly prescribed diabetes medications.